Teva moves to independence in Japan as it buys out Kowa joint venture
This article was originally published in Scrip
Teva Pharmaceutical Industries is paying $150 million to acquire the 50% of its Japanese generics joint venture with Kowa that it does not already own, in a further expansion of the Israeli group's interests in this steadily growing market.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context